NCT lookup

Inclusion Criteria:

* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
* Participants who are of Japanese ethnicity (Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese and this also includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan)
* Participants who are of Non-Asian ethnicities. A Non-Asian Participant is defined as having both parents and grandparents who are ethnically Non-Asian.
* Body mass index within the range 18 to 32 kg/m\^2
* Male and/or female participants of non-child bearing potential

Exclusion Criteria:

* History of any clinically important disease or disorder
* History or presence of gastrointestinal, hepatic, or renal disease or condition known to interfere with absorption, distribution, metabolism or excretion of drugs
* Participants with known autoimmune disease or on-treatment with immune-modulatory drugs
* Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first dose of study intervention
* Any clinically significant cardiovascular event within the last 6 months prior to the Screening Visit
* Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results and any abnormal vital signs
* Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-Lead ECG
* Blood dyscrasias with increased risk of bleeding including idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura or symptoms of increased risk of bleeding
* History of major bleed or high-risk of bleeding diathesis
* Participants with a positive diagnostic nucleic acid test for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), at Screening Visit. Participants who test positive for Coronavirus disease 2019 (COVID-19) at Screening Visit
* Participants with a significant COVID-19 illness within 6 months of enrollment
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity
* Received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days of last Follow-up to first dose of study intervention of this study or 5 half-lives from last dose to first dose of study intervention, whichever is the longest
* Participants who have previously received AZD2693
* Previous enrollment or randomization into the present study

• Sumida-ku, Japan